ALPHA 1-ANTITRYPSIN DEFICIENCY
Clinical trials for ALPHA 1-ANTITRYPSIN DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ALPHA 1-ANTITRYPSIN DEFICIENCY trials appear
Sign up with your email to follow new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human test of new Alpha-1 drug halted after early phase
Disease control TerminatedThis early-stage study tested a new drug called ARC-AAT to see if it was safe and could lower harmful protein levels in people with Alpha-1 Antitrypsin Deficiency, a genetic condition that can damage the lungs and liver. The trial involved 65 healthy volunteers and patients with …
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Experimental drug tested for rare genetic lung disease
Disease control TerminatedThis study tested whether the drug VX-864 could help people with a specific genetic form of Alpha-1 antitrypsin deficiency. Researchers enrolled 14 participants with the PiZZ genotype to receive the drug for 48 weeks. The trial was terminated early, and researchers measured chang…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC